Regulation of appetite to treat obesity

References

• James WP. The epidemiology of obesity: the size of the problem. J. Intern. Med.263(4), 336–352 (2008).
   PubMed Web of Science ®Google Scholar
• WHO. Reducing Risks, Promoting Healthy Life. Campanini B (Ed.). World Health Organization, Geneva, Switzerland (2002).
   Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA303(3), 235–241 (2010).
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007–2008. JAMA303(3), 242–249 (2010).
   PubMed Web of Science ®Google Scholar
• Daniels J. Obesity: America’s epidemic. Am. J. Nurs.106(1), 40–49, quiz 49–50 (2006).
   PubMedGoogle Scholar
• Dehghan M, Akhtar-Danesh N, Merchant AT. Childhood obesity, prevalence and prevention. Nutr. J.4, 24 (2005).
   PubMed Web of Science ®Google Scholar
• Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. Obes. Rev.5(Suppl. 1), 4–104 (2004).
   PubMedGoogle Scholar
• Kopelman P. Health risks associated with overweight and obesity. Obes Rev.8(Suppl. 1), 13–17 (2007).
   PubMed Web of Science ®Google Scholar
• Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Affairs21(2), 245–253 (2002).
   PubMed Web of Science ®Google Scholar
• Sturm R. Increases in morbid obesity in the USA: 2000–2005. Public Health121(7), 492–496 (2007).
   PubMed Web of Science ®Google Scholar
• Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology132(6), 2226–2238 (2007).
   PubMed Web of Science ®Google Scholar
• Miller ER 3rd, Erlinger TP, Young DR et al. Results of the diet, exercise, and weight loss intervention trial (DEW-IT). Hypertension40(5), 612–618 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ. Beneficial health effects of modest weight loss. Int. J. Obes.16(6), 397–415 (1992).
   PubMed Web of Science ®Google Scholar
• Sarwer DB, von Sydow Green A, Vetter ML, Wadden TA. Behavior therapy for obesity: where are we now? Curr. Opin. Endocrinol. Diabetes Obes.16(5), 347–352 (2009).
   PubMed Web of Science ®Google Scholar
• Perri M, Corsica J. Improving the maintenance of weight lost in behavioral treatment of obesity. In: Handbook of Obesity Treatment. Wadden T, Stunkard A (Eds). Guilford Press, NY, USA, 357–379 (2002).
   Google Scholar
• Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. J. Am. Med. Assoc.292(14), 1724–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med.351(26), 2683–2693 (2004).
   PubMed Web of Science ®Google Scholar
• Maggard MA, Shugarman LR, Suttorp M et al. Meta-analysis: surgical treatment of obesity. Ann. Intern. Med.142(7), 547–559 (2005).
   PubMed Web of Science ®Google Scholar
• Cote GA, Edmundowicz SA. Emerging technology: endoluminal treatment of obesity. Gastrointest. Endosc.70(5), 991–999 (2009).
   PubMed Web of Science ®Google Scholar
• Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet352(9123), 167–172 (1998).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. J. Am. Med. Assoc.281(3), 235–242 (1999).
   PubMed Web of Science ®Google Scholar
• James WPT, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet356(Suppl.), 2119–2125 (2000).
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med.337(9), 581–588 (1997).
   PubMed Web of Science ®Google Scholar
• Diets, drugs and surgery for weight loss. Treatment Guidelines from the Medical Letter6(68), 23–28 (2008).
   Google Scholar
• Bays HE. Current and investigational anti-obesity agents and obesity therapeutic treatment targets. Obes. Res.12(8), 1197–1211 (2004).
   PubMedGoogle Scholar
• Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet369(9555), 71–77 (2007).
   PubMed Web of Science ®Google Scholar
• Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ335(7631), 1194–1199 (2007).
   PubMed Web of Science ®Google Scholar
• Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Ann. Rev. Pharmacol. Toxicol.47, 565–592 (2007).
   PubMed Web of Science ®Google Scholar
• Brobeck JR. Mechanism of the development of obesity in animals with hypothalamic lesions. Physiol. Rev.26, 541–559 (1946).
   PubMed Web of Science ®Google Scholar
• Anand BK, Brobeck JR. Hypothalamic control of food intake in rats and cats. Yale J. Biol. Med.24, 123–140 (1951).
   PubMed Web of Science ®Google Scholar
• Sclafani A. Neural pathways involved in the ventromedial hypothalamic lesion syndrome in the rat. J. Comp. Physiol. Psychol.77(1), 70–96 (1971).
   PubMedGoogle Scholar
• Sclafani A, Kirchgessner A. The role of the medial hypothalamus in the control of food intake: an update. Feeding Behav.27–66 (1986).
   Google Scholar
• Stellar E. The physiology of motivation. Psychol. Rev.61(1), 5–22 (1954).
   PubMed Web of Science ®Google Scholar
• Wynne K, Stanley S, McGowan B, Bloom SR. Appetite control. J. Endocrinol.184(2), 291–318 (2005).
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature404(6778), 661–671 (2000).
   PubMed Web of Science ®Google Scholar
• Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science307(5717), 1909–1914 (2005).
   PubMedGoogle Scholar
• Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortlnergic neurons in feeding and the Agouti obesity syndrome. Nature385(6612), 165–168 (1997).
   PubMed Web of Science ®Google Scholar
• Huszar D, Lynch CA, Fairchild-Huntress V et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell88(1), 131–141 (1997).
   PubMed Web of Science ®Google Scholar
• Argyropoulos G, Rankinen T, Neufeld DR et al. A polymorphism in the human Agouti-related protein is associated with late-onset obesity. J. Clin. Endocrinol. Metab.87(9), 4198–4202 (2002).
   PubMed Web of Science ®Google Scholar
• Kristensen P, Judge ME, Thim L et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature393(6680), 72–76 (1998).
   PubMed Web of Science ®Google Scholar
• Abbott CR, Rossi M, Wren AM et al. Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei. Endocrinology142(8), 3457–3463 (2001).
   PubMed Web of Science ®Google Scholar
• Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept.65(3), 165–174 (1996).
   PubMed Web of Science ®Google Scholar
• Swart I, Jahng JW, Overton JM, Houpt TA. Hypothalamic NPY, AgRP, and POMC mRNA responses to leptin and refeeding in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol.283(5), R1020–R1026 (2002).
   PubMed Web of Science ®Google Scholar
• Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of AgRP and NPY in fasting-activated hypothalamic neurons. Nat. Neurosci.1(4), 271–272 (1998).
   PubMed Web of Science ®Google Scholar
• Inui A. Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol. Sci.20(2), 43–46 (1999).
   PubMed Web of Science ®Google Scholar
• King PJ, Widdowson PS, Doods HN, Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J. Neurochem.73(2), 641–646 (1999).
   PubMedGoogle Scholar
• Shutter JR, Graham M, Kinsey AC, Scully S, Lüthy R, Stark KL. Hypothalamic expression of ART, a novel gene related to Agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev.11(5), 593–602 (1997).
   PubMed Web of Science ®Google Scholar
• Rossi M, Kim MS, Morgan DGA et al. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of α-melanocyte stimulating hormone in vivo. Endocrinology139(10), 4428–4431 (1998).
   PubMed Web of Science ®Google Scholar
• Small CJ, Kim MS, Stanley SA et al. Effects of chronic central nervous system administration of Agouti-related protein in pair-fed animals. Diabetes50(2), 248–254 (2001).
   PubMedGoogle Scholar
• Ollmann MM, Wilson BD, Yang YK et al. Antagonism of central melanocortin receptors in vitro and in vivo by Agouti-related protein. Science278(5335), 135–138 (1997).
   PubMed Web of Science ®Google Scholar
• Fekete C, Légrádi G, Mihály E et al. α-melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J. Neurosci.20(4), 1550–1558 (2000).
   PubMed Web of Science ®Google Scholar
• Fekete C, Sarkar S, Rand WM et al. Agouti-related protein (AgRP) has a central inhibitory action on the hypothalamic-pituitary-thyroid (HPT) axis; comparisons between the effect of AgRP and neuropeptide Y on energy homeostasis and the HPT axis. Endocrinology143(10), 3846–3853 (2002).
   PubMed Web of Science ®Google Scholar
• Sarkar S, Lechan RM. Central administration of neuropeptide Y reduces α-melanocyte-stimulating hormone-induced cyclic adenosine 5´-monophosphate response element binding protein (CREB). Endocrinology144(1), 281–291 (2003).
   PubMedGoogle Scholar
• Qu D, Ludwig DS, Gammeltoft S et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature380(6571), 243–247 (1996).
   PubMed Web of Science ®Google Scholar
• Pelleymounter MA, Cullen MJ, Wellman CL. Characteristics of BDNF-induced weight loss. Exp. Neurol.131(2), 229–238 (1995).
   PubMed Web of Science ®Google Scholar
• Yeo GSH, Connie Hung CC, Rochford J et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci.7(11), 1187–1189 (2004).
   PubMed Web of Science ®Google Scholar
• Xu B, Goulding EH, Zang K et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci.6(7), 736–742 (2003).
   PubMed Web of Science ®Google Scholar
• Ricardo JA, Tongju Koh E. Anatomical evidence of direct projections from the nucleus of the solitary tract to the hypothalamus, amygdala, and other forebrain structures in the rat. Brain Res.153(1), 1–26 (1978).
   PubMed Web of Science ®Google Scholar
• Ter Horst GJ, De Boer P, Luiten PGM, Van Willigen JD. Ascending projections from the solitary tract nucleus to the hypothalamus. A phaseolus vulgaris lectin tracing study in the rat. Neuroscience31(3), 785–797 (1989).
   PubMed Web of Science ®Google Scholar
• Szczypka MS, Kwok K, Brot MD et al. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron30(3), 819–828 (2001).
   PubMed Web of Science ®Google Scholar
• Hayward MD, Pintar JE, Low MJ. Selective reward deficit in mice lacking β-endorphin and enkephalin. J. Neurosci.22(18), 8251–8258 (2002).
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci.8(5), 585–589 (2005).
   PubMed Web of Science ®Google Scholar
• Mashiko S, Moriya R, Ishihara A et al. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Eur. J. Pharmacol.615(1–3), 113–117 (2009).
   PubMed Web of Science ®Google Scholar
• Kanatani A, Mashiko S, Murai N et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: Comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology141(3), 1011–1016 (2000).
   PubMed Web of Science ®Google Scholar
• Erondu N, Gantz I, Musser B et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metabol.4(4), 275–282 (2006).
   PubMed Web of Science ®Google Scholar
• Krishna R, Gumbiner B, Stevens C et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin. Pharmacol. Ther.86(6), 659–666 (2009).
   PubMed Web of Science ®Google Scholar
• Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr. Rev.31(4), 506–543 (2010).
   PubMed Web of Science ®Google Scholar
• Wikberg JE, Mutulis F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat. Rev. Drug Discov.7(4), 307–323 (2008).
   PubMed Web of Science ®Google Scholar
• Mitchell J, Maguire J, Davenport A. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br. J. Pharmacol.158(1), 87–103 (2009).
   PubMedGoogle Scholar
• Thompson EL, Murphy KG, Todd JF et al. Chronic administration of NMU into the paraventricular nucleus stimulates the HPA axis but does not influence food intake or body weight. Biochem. Biophys. Res. Commun.323(1), 65–71 (2004).
   PubMedGoogle Scholar
• Novak CM, Zhang M, Levine JA. Sensitivity of the hypothalamic paraventricular nucleus to the locomotor-activating effects of neuromedin U in obesity. Brain Res.1169(1), 57–68 (2007).
   PubMedGoogle Scholar
• Moran TH. Cholecystokinin and satiety: current perspectives. Nutrition16(10), 858–865 (2000).
   PubMed Web of Science ®Google Scholar
• Crawley JN. Biological actions of cholecystokinin. Peptides15(4), 731–755 (1994).
   PubMed Web of Science ®Google Scholar
• Moran TH, Baldessarini AR, Salorio CF, Lowery T, Schwartz GJ. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am. J. Physiol.272(4 Pt. 2) R1245–R1251 (1997).
   PubMed Web of Science ®Google Scholar
• Moran TH, Shnayder L, Hostetler AM, McHugh PR. Pylorectomy reduces the satiety action of cholecystokinin. Am. J. Physiol.255(6) R1059–R1063 (1988).
   PubMed Web of Science ®Google Scholar
• Moran TH, Bi S. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. Philos. Trans. R. Soc. Lond. B. Biol. Sci.361(1471), 1211–1218 (2006).
   PubMed Web of Science ®Google Scholar
• Beglinger C, Degen L, Matzinger D, D’Amato M, Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am. J. Physiol.280(4) R1149–1154 (2001).
   PubMed Web of Science ®Google Scholar
• Asin KE, Bednarz L. Differential effects of CCK-JMV-180 on food intake in rats and mice. Pharmacol. Biochem. Behav.42(2), 291–295 (1992).
   PubMedGoogle Scholar
• Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature302(5910), 703–706 (1983).
   PubMed Web of Science ®Google Scholar
• Lukaszewski L, Praissman M. Effect of continuous infusions of CCK-8 on food intake and body and pancreatic weights in rats. Am. J. Physiol.254(1), R17–R22 (1988).
   PubMed Web of Science ®Google Scholar
• West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am. J. Physiol.15(5), R776–R787 (1984).
   Google Scholar
• Fong TM. Advances in anti-obesity therapeutics. Expert Opin. Investig. Drugs14(3), 243–250 (2005).
   PubMed Web of Science ®Google Scholar
• Matson CA, Ritter RC. Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am. J. Physiol.276(4 Pt 2), R1038–R1045 (1999).
   PubMed Web of Science ®Google Scholar
• Plusczyk T, Westermann S, Rathgeb D, Feifel G. Acute pancreatitis in rats: effects of sodium taurocholate, CCK-8, and Sec on pancreatic microcirculation. Am. J. Physiol.272(2 Pt 1), G310–G320 (1997).
   PubMed Web of Science ®Google Scholar
• Pandol SJ, Periskic S, Gukovsky I et al. Ethanol diet increases the sensitivity of rats to pancreatitis induced by cholecystokinin octapeptide. Gastroenterology117(3), 706–716 (1999).
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab.3(3), 153–165 (2006).
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology132(6), 2131–2157 (2007).
   PubMed Web of Science ®Google Scholar
• Brubaker PL. The glucagon-like peptides: Pleiotropic regulators of nutrient homeostasis. Ann. NY Acad. Sci.10, 10–26 (2006).
   Google Scholar
• Meeran K, O’Shea D, Edwards CMB et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7–36) amide or exendin-(9–39) alters body weight in the rat. Endocrinology140(1), 244–250 (1999).
   PubMed Web of Science ®Google Scholar
• Turton MD, O’Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature379(6560), 69–72 (1996).
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest.101(3), 515–520 (1998).
   PubMed Web of Science ®Google Scholar
• Näslund E, King N, Mansten S et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr.91(3), 439–446 (2004).
   PubMed Web of Science ®Google Scholar
• Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7–36) amide’s central inhibition of feeding and peripheral inhibition of are abolished by neonatal monosodium glutamate treatment. Diabetes47(4), 530–537 (1998).
   PubMedGoogle Scholar
• Abbott CR, Monteiro M, Small CJ et al. The inhibitory effects of peripheral administration of peptide YY 3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem–hypothalamic pathway. Brain Res.1044(1), 127–131 (2005).
   PubMed Web of Science ®Google Scholar
• Furuse M, Matsumoto M, Mori R, Sugahara K, Kano K, Hasegawa S. Influence of fasting and neuropeptide Y on the suppressive food intake induced by intracerebroventricular injection of glucagon-like peptide-1 in the neonatal chick. Brain Res.764(1–2), 289–292 (1997).
   PubMedGoogle Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem.214(3), 829–835 (1993).
   PubMedGoogle Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: systematic review and meta-analysis. J. Am. Med. Assoc.298(2), 194–206 (2007).
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with Type 2 diabetes. Diabetes Care30(6), 1487–1493 (2007).
   PubMed Web of Science ®Google Scholar
• Beglinger C, Poller B, Arbit E et al. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3–36: a proof-of-concept study in healthy subjects. Clin. Pharmacol. Ther.84(4), 468–474 (2008).
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Benefit–risk assessment of exenatide in the therapy of Type 2 diabetes mellitus. Drug Saf.33(2), 87–100 (2010).
   PubMed Web of Science ®Google Scholar
• Dakin CL, Gunn I, Small CJ et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology142(10), 4244–4250 (2001).
   PubMed Web of Science ®Google Scholar
• Dakin CL, Small CJ, Batterham RL et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology145(6), 2687–2695 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen MA, Ellis SM, Le Roux CW et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab.88(10), 4696–4701 (2003).
   PubMed Web of Science ®Google Scholar
• Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology127(2), 546–558 (2004).
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes54(8), 2390–2395 (2005).
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes.30(12), 1729–1736 (2006).
   PubMed Web of Science ®Google Scholar
• Adrian TE, Ferri GL, Bacarese-Hamilton AJ. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology89(5), 1070–1077 (1985).
   PubMed Web of Science ®Google Scholar
• Liu CD, Aloia T, Adrian TE et al. Peptide YY: A potential proabsorptive hormone for the treatment of malabsorptive disorders. Am. Surg.62(3), 232–236 (1996).
   PubMed Web of Science ®Google Scholar
• Adrian TE, Savage AP, Sagor GR. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology89(3), 494–499 (1985).
   PubMed Web of Science ®Google Scholar
• Adams SH, Won WB, Schonhoff SE, Leiter AB, Paterniti JR Jr. Effects of peptide YY[3–36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology145(11), 4967–4975 (2004).
   PubMed Web of Science ®Google Scholar
• Chelikani PK, Haver AC, Heidelberger RD. Intravenous infusion of peptide YY(3–36) potently inhibits food intake in rats. Endocrinology146(2), 879–888 (2005).
   PubMed Web of Science ®Google Scholar
• Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY3–36 physiologically inhibits food intake. Nature418(6898), 650–654 (2002).
   PubMed Web of Science ®Google Scholar
• Batterham RL, Heffron H, Kapoor S et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab.4(3), 223–233 (2006).
   PubMed Web of Science ®Google Scholar
• Le Roux CW, Batterham RL, Aylwin SJB et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology147(1), 3–8 (2006).
   PubMed Web of Science ®Google Scholar
• Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology132(6), 2116–2130 (2007).
   PubMed Web of Science ®Google Scholar
• Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3–36. N. Engl. J. Med.349(10), 941–948 (2003).
   PubMed Web of Science ®Google Scholar
• Degen L, Oesch S, Casanova M et al. Effect of peptide YY3–36 on food intake in humans. Gastroenterology129(5), 1430–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Gantz I, Erondu N, Mallick M et al. Efficacy and safety of intranasal peptide YY3–36 for weight reduction in obese adults. J. Clin. Endocrinol. Metab.92(5), 1754–1757 (2007).
   PubMed Web of Science ®Google Scholar
• Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature402(6762), 656–660 (1999).
   PubMed Web of Science ®Google Scholar
• Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol. Cell. Biol.23(22), 7973–7981 (2003).
   PubMed Web of Science ®Google Scholar
• Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature407(6806), 908–913 (2000).
   PubMed Web of Science ®Google Scholar
• Wren AM, Small CJ, Abbott CR et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes50(7–12), 2540–2547 (2001).
   PubMed Web of Science ®Google Scholar
• Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes50(4), 707–709 (2001).
   PubMed Web of Science ®Google Scholar
• Otto B, Cuntz U, Fruehauf E et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol.145(5), 669–673 (2001).
   PubMed Web of Science ®Google Scholar
• Tolle V, Kadem M, Bluet-Pajot MT et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J. Clin. Endocrinol. Metab.88(1), 109–116 (2003).
   PubMed Web of Science ®Google Scholar
• Guan XM, Yu H, Palyha OC et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res. Mol. Brain Res.48(1), 23–29 (1997).
   PubMedGoogle Scholar
• Gnanapavan S, Kola B, Bustin SA et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab.87(6), 2988–2991 (2002).
   PubMed Web of Science ®Google Scholar
• Date Y, Murakami N, Toshinai K et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology123(4), 1120–1128 (2002).
   PubMed Web of Science ®Google Scholar
• Naleid AM, Grace MK, Cummings DE, Levine AS. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides26(11), 2274–2279 (2005).
   PubMed Web of Science ®Google Scholar
• Carlini VP, Varas MM, Cragnolini AB, Schiöth HB, Scimonelli TN, De Barioglio SR. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem. Biophys. Res. Commun.313(3), 635–641 (2004).
   PubMed Web of Science ®Google Scholar
• Zorrilla EP, Iwasaki S, Moss JA et al. Vaccination against weight gain. Proc. Natl Acad. Sci. USA103(35), 13226–13231 (2006).
   PubMed Web of Science ®Google Scholar
• Moran TH, Dailey MJ. Gut peptides: targets for anti-obesity drug development? Endocrinology150(6), 2526–2530 (2009).
   PubMed Web of Science ®Google Scholar
• Yang J, Zhao TJ, Goldstein JL, Brown MS. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc. Natl Acad. Sci.USA105(31), 10750–10755 (2008).
   PubMed Web of Science ®Google Scholar
• Hort Y, Baker E, Sutherland GR, Shine J, Herzog H. Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1. Genomics26(1), 77–83 (1995).
   PubMed Web of Science ®Google Scholar
• Adrian TE, Bloom SR, Bryant MG. Distribution and release of human pancreatic polypeptide. Gut17(12), 940–944 (1976).
   PubMed Web of Science ®Google Scholar
• Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos. Trans. R. Soc. Lond. B. Biol. Sci.361(1471), 1187–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Malaisse-Lagae F, Carpentier JL, Patel YC. Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis. Experientia33(7), 915–917 (1977).
   PubMedGoogle Scholar
• Asakawa A, Inui A, Yuzuriha H et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology124(5), 1325–1336 (2003).
   PubMed Web of Science ®Google Scholar
• Ueno N, Inui A, Iwamoto M et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology117(6), 1427–1432 (1999).
   PubMed Web of Science ®Google Scholar
• Reinehr T, Enriori PJ, Harz K, Cowley MA, Roth CL. Pancreatic polypeptide in obese children before and after weight loss. Int. J. Obes.30(10), 1476–1481 (2006).
   Web of Science ®Google Scholar
• Fujimoto S, Inui A, Kiyota N et al. Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa. Biol. Psychiatry41(10), 1068–1070 (1997).
   PubMed Web of Science ®Google Scholar
• Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology115(1), 427–429 (1984).
   PubMed Web of Science ®Google Scholar
• Larsen PJ, Kristensen P. The neuropeptide Y (Y4) receptor is highly expressed in neurones of the rat dorsal vagal complex. Brain Res. Mol. Brain Res.48(1), 1–6 (1997).
   PubMedGoogle Scholar
• Whitcomb DC, Taylor IL, Vigna SR. Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am. J. Physiol.259(4 Pt 1), G687–G691 (1990).
   PubMedGoogle Scholar
• Batterham RL, Le Roux CW, Cohen MA et al. Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab.88(8), 3989–3992 (2003).
   PubMed Web of Science ®Google Scholar
• Adrian TE, Greenberg GR, Besterman HS, Bloom SR. Pharmacokinetics of pancreatic polypeptide in man. Gut19(10), 907–909 (1978).
   PubMed Web of Science ®Google Scholar
• Pittner RA, Albrandt K, Beaumont K et al. Molecular physiology of amylin. J. Cell.Biochem.55(Suppl.), 19–28 (1994).
   PubMedGoogle Scholar
• Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet339(8802), 1179–1180 (1992).
   PubMed Web of Science ®Google Scholar
• Koda JE, Fineman MS, Kolterman OG, Caro JF. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes44(Suppl. 1) 238A (1995).
   Google Scholar
• Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC. Amylin: a novel action in the brain to reduce body weight. Endocrinology141(2), 850–853 (2000).
   PubMed Web of Science ®Google Scholar
• Rushing PA, Hagan MM, Seeley RJ et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology142(11), 5035–5038 (2001).
   PubMedGoogle Scholar
• Gebre-Medhin S, Mulder H, Pekny M et al. IAPP (amylin) null mutant mice; plasma levels of insulin and glucose, body weight and pain responses. Diabetologia40, A26 (1997).
   Google Scholar
• Devine E, Young AA. Weight gain in male and female mice with amylin gene knockout. Diabetes47(Suppl. 1), A317 (1998).
   Web of Science ®Google Scholar
• Cooper GJS. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr. Rev.15(2), 163–201 (1994).
   PubMedGoogle Scholar
• Young AA, Wang MW, Gedulin B, Rink TJ, Pittner R, Beaumont K. Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism44(12), 1581–1589 (1995).
   PubMed Web of Science ®Google Scholar
• McLatchie LM, Fraser NJ, Main MJ et al. RAMPS regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature393(6683), 333–339 (1998).
   PubMed Web of Science ®Google Scholar
• Muff R, Bühlmann N, Fischer JA, Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology140(6), 2924–2927 (1999).
   PubMed Web of Science ®Google Scholar
• Young A, Moore C, Herich J, Beaumont K. Neuroendocrine actions of amylin. In: The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin. Poyner D, Marshall I, Brain SD (Eds). Lands Bioscience, TX, USA, 91–102 (2000).
   Google Scholar
• Jodka C, Green D, Young A, Gedulin B. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve. Diabetes45(Suppl. 2), A235 (1996).
   Web of Science ®Google Scholar
• Edwards GL, Gedulin BR, Jodka C, Dilts RP, Miller CC, Young A. Area postrema (AP)-lesions block the regulation of gastric emptying by amylin. Neurogastroenterol. Motil.10(4), 26 (1998).
   Google Scholar
• Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int. J. Obes.25(7), 1005–1011 (2001).
   PubMed Web of Science ®Google Scholar
• Edelman SV, Weyer C. Unresolved challenges with insulin therapy in Type 1 and Type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol. Ther.4(2), 175–189 (2002).
   PubMedGoogle Scholar
• Young AA, Vine W, Gedulin BR et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev. Res.37(4), 231–248 (1996).
   Web of Science ®Google Scholar
• Ratner RE, Want LL, Fineman MS et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with Type 2 diabetes. Diabetes Technol. Ther.4(1), 51–61 (2002).
   PubMedGoogle Scholar
• Hollander PA, Levy P, Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with Type 2 diabetes. Diabetes Care26(3), 784–790 (2003).
   PubMed Web of Science ®Google Scholar
• Whitehouse F, Kruger DF, Fineman M et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in Type 1 diabetes. Diabetes Care25(4), 724–730 (2002).
   PubMed Web of Science ®Google Scholar
• Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with Type 2 diabetes: a pooled post hoc analysis. Metabolism52(12), 1638–1642 (2003).
   PubMed Web of Science ®Google Scholar
• Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. Obes. Res.4(1), 91–95 (1996).
   PubMedGoogle Scholar
• Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science269(5223), 543–546 (1995).
   PubMed Web of Science ®Google Scholar
• Pelleymounter MA, Cullen MJ, Baker MB et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science269(5223), 540–543 (1995).
   PubMed Web of Science ®Google Scholar
• Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature387(6636), 903–908 (1997).
   PubMed Web of Science ®Google Scholar
• Farooqi IS, O’Rahilly S. Monogenic obesity in humans. Recent Prog. Horm. Res.59, 409–424 (2005).
   Google Scholar
• Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med.334(5), 292–295 (1996).
   PubMed Web of Science ®Google Scholar
• Ahlma RS, Prabakaran D, Mantzoros C et al. Role of leptin in the neuroendocrine response to fasting. Nature382(6588), 250–252 (1996).
   PubMedGoogle Scholar
• Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell83(7), 1263–1271 (1995).
   PubMed Web of Science ®Google Scholar
• Münzberg H, Myers Jr MG. Molecular and anatomical determinants of central leptin resistance. Nat. Neurosci.8(5), 566–570 (2005).
   PubMed Web of Science ®Google Scholar
• Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog. Horm. Res.59(1), 287–304 (2004).
   PubMedGoogle Scholar
• Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am. J. Physiol. Endocrinol. Metab.297(6), E1247–E1259 (2009).
   PubMed Web of Science ®Google Scholar
• Cheung CC, Clifton DK, Steiner RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology138(10), 4489–4492 (1997).
   PubMed Web of Science ®Google Scholar
• Baskin DG, Breininger JF, Schwartz MW. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes48(4), 828–833 (1999).
   PubMed Web of Science ®Google Scholar
• Tang-Christensen M, Holst JJ, Hartmann B, Vrang N. The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. Neuroreport10(6), 1183–1187 (1999).
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Baskin DG, Bukowski TR et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes45(4), 531–535 (1996).
   PubMed Web of Science ®Google Scholar
• Stephens TW, Basinski M, Bristow PK et al. The role of neuropeptide Y in the anti-obesity action of the obese gene product. Nature377(6549), 530–532 (1995).
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Seeley RJ, Woods SC et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes46(12), 2119–2123 (1997).
   PubMed Web of Science ®Google Scholar
• Ozcan L, Ergin AS, Lu A et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab.9(1), 35–51 (2009).
   PubMed Web of Science ®Google Scholar
• Holland WL, Miller RA, Wang ZV et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med.17(1), 55–63 (2010).
   PubMedGoogle Scholar
• Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA105(20), 7257–7262 (2008).
   PubMed Web of Science ®Google Scholar
• Fernández-Real JM, Sanchis D, Ricart W et al. Plasma oestrone-fatty acid ester levels are correlated with body fat mass in humans. Clin. Endocrinol. (Oxf.).50(2), 253–260 (1999).
   PubMedGoogle Scholar
• Sanchis D, Balada F, Del Mar Grasa M et al. Oleoyl-estrone induces the loss of body fat in rats. Int. J. Obes.20(6), 588–594 (1996).
   Web of Science ®Google Scholar
• Sanchis D, Balada F, Picó C et al. Rats receiving the slimming agent oleoyl-estrone in liposomes (Merlin- 2) decrease food intake but maintain thermogenesis. Arch. Physiol. Biochem.105(7), 663–672 (1997).
   PubMed Web of Science ®Google Scholar
• Adán C, Cabot C, Vilà R et al. Oleoyl-estrone treatment affects the ponderostat setting differently in lean and obese Zucker rats. Int. J. Obes.23(4), 366–373 (1999).
   Google Scholar
• Remesar X, Guijarro P, Torregrosa C et al. Oral oleoyl-estrone induces the rapid loss of body fat in Zucker lean rats fed a hyperlipidic diet. Int. J. Obes.24(11), 1405–1412 (2000).
   Google Scholar
• Strassburg S, Pfluger PT, Chaudhary N et al. Action profile of the anti-obesity drug candidate oleoyl-estrone in rats. Obesity (Silver Spring)18(12), 2260–2267 (2010).
   PubMedGoogle Scholar
• Alemany M, Fernández-López JA, Petrobelli A, Granada M, Foz M, Remesar X. Weight loss in a patient with morbid obesity under treatment with oleoyl-estrone. Med. Clin. (Barc.).121(13), 496–499 (2003).
   PubMedGoogle Scholar
• Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature404(6778), 661–671 (2000).
   PubMed Web of Science ®Google Scholar
• Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br. J. Clin. Pharmacol.68(6), 852–860 (2009).
   PubMed Web of Science ®Google Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M et al. Rational design of a combination medication for the treatment of obesity. Obesity17(1), 30–39 (2009).
   PubMed Web of Science ®Google Scholar
• Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and Type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med.4(10), 1152–1156 (1998).
   PubMed Web of Science ®Google Scholar
• Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women. Obesity17(3), 494–503 (2009).
   PubMed Web of Science ®Google Scholar
• Sonnenberg GE, Matfin G, Reinhardt RR. Drug treatments for obesity: where are we heading and how do we get there? Br. J. Diab. Vasc. Dis.7(3), 111–118 (2007).
   Google Scholar
• Becskei C, Bilik KU, Klussmann S, Jarosch F, Lutz TA, Riediger T. The anti-ghrelin Spiegelmer NOX-B11-3 blocks ghrelin- but not fasting-induced neuronal activation in the hypothalamic arcuate nucleus. J. Neuroendocrinol.20(1), 85–92 (2008).
   PubMedGoogle Scholar
• Fong TM, Guan XM, Marsh DJ et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2 -[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J. Pharmacol. Exp. Ther.321(3), 1013–1022 (2007).
   PubMed Web of Science ®Google Scholar